ACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.
On July 18, 2017, Acceleron Pharma Inc. (the "Company") and MIT 128 Sidney Leasehold LLC (successor in interest to Massachusetts Institute of Technology) ("Landlord"), entered into an amendment (the "Lease Amendment") to that certain Indenture of Lease, dated as of May 20, 2008, between the Company and Landlord (the "Lease"), relating to the Company's lease of approximately 37,700 rentable square feet of office and manufacturing space located at 128 Sidney Street, Cambridge, Massachusetts ("128 Sidney").
Under theLease Amendment, the initial term of the Lease is extended for an additional five years, commencing on October1, 2018, and unless earlier terminated, ending on September 30, 2023. Upon certain terms and conditions set forth in theLease, the Company has the right to extend the Lease for one additional five year period. The Company will pay annual rent of $65.00 per rentable square foot beginning on October 1, 2018, subject to a 3% increase annually thereafter.
In connection with the Lease Amendment and the amendment of that certain Indenture of Lease, dated as of June 13, 2008, between the Company and MIT 149 Sidney Leasehold LLC ("149 Landlord"), relating to the Company's lease of approximately 37,116 rentable square feet of office and lab space located at 149 Sidney Street, Cambridge, Massachusetts ("149 Sidney"), Landlord and 149 Landlord will reimburse the Company up to $200,000 for certain work to be performed by the Company at 128 Sidney and 149 Sidney, and up to an additional $500,000 for the replacement of certain HVAC units, water heaters and other base building improvements at 128 Sidney and 149 Sidney.
The foregoing description of the terms of the Lease Amendmentdoes not purport to be complete and is qualified in its entirety by reference to the full text of the Lease Amendment, a copy of which is attached hereto as Exhibit 10.1 to this Current Report on Form8-K.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
|
Exhibit Number |
DescriptionofExhibit |
|
10.1 |
First Amendment to Lease, dated as of July 18, 2017, between MIT 128 Sidney Leasehold LLC and Acceleron PharmaInc. |
ACCELERON PHARMA INC ExhibitEX-10.1 2 xlrn-20170719form8xkex101.htm EXHIBIT 10.1 Exhibit Exhibit 10.1FIRST AMENDMENT TO LEASE This First Amendment to Lease (this “First Amendment”) is made as of July 18,…To view the full exhibit click here
About ACCELERON PHARMA INC. (NASDAQ:XLRN)
Acceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company’s pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.
